Unaudited Consolidated Statement of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (682,798)	$ (540,068)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	100,766	68,615
Loss on derivative liability	40,000	165,000
Depreciation and amortization	138,256	110,378
Changes in operating assets and liabilities:
Accounts receivable	1,850,375	(4,865)
Accrued interest - loans payable related party	(1,280)	(27,560)
Accrued interest - loans payable third party	3,675	4,075
Other current assets	2,399	1,026
Accounts payable and accrued expenses	(1,242,569)	327,263
Net cash provided by operating activities	208,824	103,864
Cash flows from investing activities:
Purchase of patents		(75,000)
Net cash used in investing activities		(75,000)
Cash flows from financing activities:
Repayment of purchase price of patents	(194,386)	(75,000)
Net cash used in financing activities	(194,386)	(75,000)
Net increase (decrease) in cash and cash equivalents	14,438	(46,136)
Cash and cash equivalents at beginning of period	537,198	166,911
Cash and cash equivalents at end of period	551,636	120,775
Non-cash investing and financing activities
Accounts payable for patent purchase, net of imputed interest of $0 and $336,781, respectively		1,238,219
Supplemental disclosure of cash flow information:
Income taxes including foreign taxing authorities withheld taxes of $0 and $0 during the periods ended March 31, 2020, and 2019 respectively.	225	225
Interest	$ 117,780	$ 117,780